	Application No.	Applicant(s)
Office Action Summary	09/652,548	KUGLER ET AL.
	Examiner	Art Unit
	Michael J Milano	3738
The MAILING DATE of this communicati eriod for Reply	on appears on the cover sheet with t	he correspondence address
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNICAT - Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communica - If the period for reply specified above is less than thirty (30) day - If NO period for reply is specified above, the maximum statutory - Failure to reply within the set or extended period for reply will, b - Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	FION. CFR 1.136(a). In no event, however, may a reply letion. s, a reply within the statutory minimum of thirty (30) y period will apply and will expire SIX (6) MONTHS by statute, cause the application to become ABAND are mailing date of this communication, even if timely	be timely filed) days will be considered timely, from the mailing date of this communication, ONED (35 U.S.C. § 133).
1) Responsive to communication(s) filed o		
/	This action is non-final.	
3) Since this application is in condition for closed in accordance with the practice	allowance except for formal matters under <i>Ex parte Quayle</i> , 1935 C.D. 1	s, prosecution as to the merits is 1, 453 O.G. 213.
Disposition of Claims		
4) Claim(s) 37-46 is/are pending in the app	plication.	
4a) Of the above claim(s) is/are w	rithdrawn from consideration.	
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>37-46</u> is/are rejected.	•	
7) Claim(s) is/are objected to.		
8) Claim(s) are subject to restriction	and/or election requirement.	
Application Papers		
9)☐ The specification is objected to by the Ex	aminer.	
10) The drawing(s) filed on is/are: a)	\square accepted or b) \square objected to by the $oldsymbol{\mathfrak{l}}$	Examiner.
Applicant may not request that any objection		
11) The proposed drawing correction filed on	ı is: a)∏ approved b)∏ disa _l	pproved by the Examiner.
If approved, corrected drawings are require		
12) The oath or declaration is objected to by	the Examiner.	
Priority under 35 U.S.C. §§ 119 and 120	·	
13) Acknowledgment is made of a claim for	foreign priority under 35 U.S.C. § 11	19(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
 Certified copies of the priority doc 		
2. Certified copies of the priority doc		
 3. Copies of the certified copies of the application from the Internation * See the attached detailed Office action for the action	nal Bureau (PCT Rule 17.2(a)).	
14) Acknowledgment is made of a claim for de		
a) ☐ The translation of the foreign langua		
attachment(s)		
1) X Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-93) X Information Disclosure Statement(s) (PTO-1449) Paper	948) 5) Notice of Infor	nmary (PTO-413) Paper No(s) mal Patent Application (PTO-152)
S. Patent and Trademark Office FO-326 (Rev. 04-01)	Office Action Summary	Part of Paper No. 5

Application/Control Number: 09/652,548

Art Unit: 3738

DETAILED ACTION

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claim 46 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 11-13 of U.S. Patent No. 6,129,756. Although the conflicting claims are not identical, they are not patentably distinct from each other. It should be noted that newly proposed claim 46 was not part of the original restriction requirement of the parent application. Claim 46 is considered to comprise subject matter similar to the elected claims in the parent application.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application

Application/Control Number: 09/652,548

Art Unit: 3738

by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Claims 37-42 are rejected under 35 U.S.C. 102(b) as being anticipated by Lunn, 5,476,506. As seen in Figures 4-5D, the graft system comprises a tubular graft component with first and second ends of larger diameter than the middle portion, a length adjustable middle (due to the bellows or pleats) and stents in both the first and second ends.

Claims 37-46 are rejected under 35 U.S.C. 102(e) as being anticipated by Fogarty, 6,123,722. As seen in Figures 3-4, The Fogarty graft system comprises a tubular graft component with first and second ends of larger diameter than the middle portion, a length adjustable middle and stents in both the first and second ends. It should be noted that the length adjustable middle can comprises both a bellows region (column 18, lines 48-55) or a telescoping region (as seen in the Figures).

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael J Milano whose telephone number is 703-308-2496. The examiner can normally be reached on M,T,TH,F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on 703-308-0858. The fax phone numbers for the organization where this application or proceeding is assigned are 703-

Art Unit: 3738

305-3590 for regular communications and 703-305-3590 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0858.

Michael J Milano Primary Examiner Art Unit 3738

mjm November 2, 2001